Promoted to lead the national commercial direction of all clot products with a focus on the integration and launch of Devoro ($400m Thrombectomy start-up).Led all pre-launch and commercial planning for launch of Wolf Thrombectomy device Built group of 10 KOL interventionalists to complete "first in man" cases and help develop new treatment algorithm

National role responsible for all of Clot Management sales. This includes all of BSC legacy Angiojet and all of BTG legacy Ekos. Approx $200M in annual sales.

BTG/Ekos was acquired by Boston Scientific, August 2019. Promoted to National role overseeing all sales responsibilities for legacy BTG EKos($100M Annual sales) business under BSC.

BTG is a British healthcare company focused on medical devices and pharmaceuticals for the treatment of vascular disease and cancer as well as antidotes for medication toxicities. Company has 1,500+ employees and $800M+ in revenue.EKOS Corporation was acquired by BTG in August of 2013. Ekos was a startup company which developed an ultrasound-assisted thrombolysis technology for the treatment of pulmonary embolism, deep vein thrombosis, and arterial occlusionsI was hired to take over the management of the Eastern US. The main goal being to help transition the team from a one product start-up organization to a three product mature sales organization. BTG acquired Novate in September of 2018 and Roxwood Medical in 2017 and now needed to learn how to grow beyond the early launch phase of an early start-up. I was able to make immediate impact through the creation of a more formal and strategic management process; beginning with the basics such as business reviews, teams calls, and strategic planning. We then layered in more sophisticated business analytic tools and developed our first leveraged contracts tying the three products together. I created a sales forecasting tool that has helped our teams get a stronger hold on their business, analyze trends, pro-actively defend new competition, and plan to deliver quarter stronger end results. My region delivered $1.4M above plan in Q4- which is the single best regional performance in company history. We signed four major leverage contracts and we are in process of evaluating many more. We have been able to manage through the transition to Boston Scientific and continue to deliver solid sales results. I am currently responsible for regional managers, sales reps, and clinical support team. The team spans Eastern 1/2 of US. - approx $50M in total sales and 45 people.

Northeast District Manager- Managed Sales team selling entire peripheral vascular product portfolio

I managed the commercial launch of the Bullfrog Micro-infusion catheter while helping to complete the "Dance" SFA trial in the USA. I created the plan to develop a commercial presence for the Bullfrog while finalizing a study to establish a clinical rationale to infuse drug in to the adventitia of the artery. I completed site initiation, budget negotiations, IRB submissions, and site initiations for the Dance study. We were able to demonstrate that you could impact the restenosis cascade by delivering drug in to the outer layer of the vessel- knowing that cell migration causing restenosis moves from Adventitia inward.I was successful in launching the Bullfrog device and finished the "Dance" trial establishing that the bullfrog could deliver an anti-inflammatory drug and positively impact vessel patency. We began to develop Champion physicians and gained a national presence through live cases, national meeting talks and presence, etc. I finalized the protocol for the "Below the Knee" trial called "Limbo" and I hired a small direct sales team. I developed a network of distributor reps that utilized to drive additional case volume and cover study cases. I worked closely with the CEO on all aspects of early commercialization including the raising of VS funding. I was able to bring over $10M of potential investment to the table for consideration.

I began as one of the first field hires and helped to build the company from Pre-FDA approval through successful $310M Acquisition. We grew national sales from $0 to approx. $30M when we were acquired by Abbot. I was a top early sales rep, one of the first regional managers, and then was promoted to the Director of sales for the Mid-atlantic, Northeast, and Canada when we were acquired. I launched the Supera stent to the US- first of its kind woven Nitinol SFA stent. I developed the launch strategy, created the clinical training program, and built our top KOL physicians. I created and ran six animal lab training sessions at CBSET in Lexington, MA which focused on physician and tech training. This hands-on lab training course helped physicians learn how to correctly deploy the Supera stent.